VB6-845
VB6-845 is Viventia’s anti-EpCAM therapeutic designed for the treatment of patients with advanced solid tumors via intravenous (IV) infusion. There are over two and a half million new cases of EpCAM-positive solid tumors diagnosed annually in the MM7. VB6-845 is a recombinant fusion protein produced in E. coli comprised of an anti-EpCAM Fab antibody fragment recombinantly fused to Viventia’s proprietary de-immunized protein payload, De-Bouganin.
First-in-man study
A first-in-man study was performed to evaluate the safety and tolerability of VB6-845 in patients with advanced solid tumors of epithelial origin. VB6-845 was administered as a monotherapy IV fusion, once weekly at two dose levels (1.0 and 2.0 mg/kg). In total, 13 patients were enrolled into 2 cohorts. Overall, VB6-845 was well tolerated with stable disease achieved in 6 out of 13 end-stage patients (lung, breast, kidney, colon, pancreas, ovarian) after 4 weeks, with one of those patients maintaining stable disease to 8 weeks and another up to 12 weeks. Interestingly, some patients showed immunogenicity to the Fab portion of the molecule; however, patient samples confirmed the successful de-immunization of De-Bouganin.
The Company has re-engineered the Fab portion, to remove T-cell epitopes, and the new molecule is poised for an IND application for Phase I clinical trials.
For more information, to download our VB6-845 Licensing Brochure
|
